Yesterday, the U.S. biotech sector showed strong momentum, with the $纳斯达克生物技术指数(NBI)$ rising 2.64% in a single day. From a structural perspective, gains were broadly distributed across small- and mid-cap innovative drug companies, with $Sarepta Therapeutics(SRPT)$ surging nearly 35% and multiple names such as $Arrowhead Research Corporation(ARWR)$ and $Arvinas Holding Company LLC(ARVN)$ rising more than 5%, indicating a clear breadth-driven rally. From a one-day performance perspective, biotech-related ETFs moved higher across the board, with stronger gains in innovative and high-beta segments.

Hi, Tigers 🐯 Despite ongoing cost pressures, the healthcare sector’s growth outlook remains constructive. An ageing population and continued breakthroughs in medical innovation continue to provide long-term support Looking to invest in this sector but don’t wanna pick individual stocks? ETFs offer a simple and cost-efficient way to gain exposure! Of course, near-term challenges are real.According to a McKinsey report dated 12 January, the US healthcare system is under increasing financial pressure. Industry operating margins are expected to fall from 11.2% in 2019 to 8.9% in 2024, with payers and healthcare providers most affected. However, analysts expect conditions to improve gradually over the next three years.With an ageing population and steady demand for new therapies, healthcare rem

Stocks have rebounded sharply in the last weeks in 2023 as investors expect a new round of Federal Reserve rate cuts. Investors kicked off 2024 by holding onto expectations for up to seven quarter-point rate cuts from the Federal Reserve in 2024, which is more than twice as much as what Fed policymakers have suggested. I would think investors would have these expectations adjusted when we get the result of the minutes from the Fed's 12-13 Dec meeting on 03 Jan at 2pm Eastern Time. So the big question is how to profit off it. Investors can outperform during the 12 months after the first rate cut if the Fed take steps to extend the length of the 10-year bull market. In this article, I would like to share on one sector plays, which is the health care. Looking at particular the health care ET